On May 18, 2017, DevicePharm and Medical Alley Association co-sponsored an event titled “Communicating Value – Marketing Success In A Value-Driven Environment”. The event, held in the iconic Guthrie Theater in downtown Minneapolis, was attended by 200 members of the Minnesota medical device, biotech, diagnostics, and pharmaceutical community.
Category Archives: Articles
On May 1, 2017, DevicePharm announced the opening of our new office in Austin, Texas. This office was developed to serve the growing medical technology industry in Austin, Houston, Dallas, and San Antonio.
Clay Wilemon, DevicePharm CEO and Chief Strategy Officer described the motivation for opening the Austin office, “Texas has over 700 medical device, biotech, diagnostics, and pharmaceutical companies.
Much-anticipated breast cancer results from the prospective, randomized clinical study known as MINDACT were published in the August 24, 2016 edition of the New England Journal of Medicine. The MINDACT study evaluated the MammaPrint® 70-Gene Breast Cancer Recurrence Assay in 6,693 patients to determine its ability to help physicians identify which early-stage breast cancer patients would, and would not, likely benefit from chemotherapy.
SkylineDx debuted its new MMprofiler™ with SKY92 campaign this year during the European Hematology Association conference in Denmark. MMprofiler with SKY92 enables physicians to quickly and confidently identify high-risk multiple myeloma patients.
DevicePharm, a marketing strategy and integrated marketing solutions firm, is pleased to announce the promotion of Joseph Bañuelos to Vice President, Creative Director. Joseph is a proven leader in brand development and campaign creation for healthcare marketing.
DevicePharm has been recognized as a Foundational Member of Medical Alley, the Minnesota-based organization focused on growing one of the world’s most prolific centers of healthcare technology and delivery innovation.
Healthcare reform is changing the way that healthcare marketers think about everything from clinical trials to product launches. New payment models, new delivery models, and HEOR mandates are all creating major changes in marketing focus for medical device, biotech, pharmaceutical, and medical diagnostics companies.
At the 2015 San Antonio Breast Cancer Symposium, Provista introduced Videssa® Breast, a breakthrough that accurately detects the presence or absence of breast cancer with a protein-based blood test. Videssa® Breast provides clinicians, and their patients, with clinical confidence, clarity and peace-of-mind about what to do next when mammography is unclear – detecting the absence or presence of breast cancer by identifying early warning signals called biomarkers.
Each year we unleash the creative beast in the DevicePharm team in a no-holds-barred Gingerbread House contest. Art directors and accountants, writers and editors, animators and account executives; everybody gets to build the gingerbread house of their dreams. And, as the winning categories indicate, some of those dreams are sweet and others may be best classified as nightmares.
OCTANe launched the 10th annual Medical Device & Investor Forum on November 2, 2015 at the Hotel Irvine by introducing an expanded vision for Orange County’s technology industry accelerator. The presentation included an introduction of the expanded brand scope and new branding elements by DevicePharm CEO & Chief Strategy Officer, Clay Wilemon.